What’s Happening
Chatter
- Advice for those moving from perm CRO to contract biopharma positions
- Choosing between Bioengineering and Biology for gene editing research — advice?
- Any advice on how to recruit participants?
- Sweden just launched a nationwide precision omics initiative – PROMISE
- Getting into the Field
- Is there an ideal day to email job applications to PIs for crc positions?
- FSP CRA Pfizer
- Anyone else noticing these ads in your reddit feeds?
- eTMF Reconciliation – HELP
- CRA and Site numbers/Protocol
- Senior project specialist looking to move up in corporate
- how are you guys landing interviews?
- Places to apply for entry level
- Four year gap and Resume
- How do I politely tell my PI the growth curve he wants me to collect is physically impossible?
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…